Panobinostat

Red

Brand Name(s):Farydak

Indication:Multiple Myeloma

Rationale:1,2,3

Considered:Feb-16

Review Date:Jan-26

Comments:
NICE TA380
Panobinostat in combination with bortezomib and dexamethasone is recommended, within its marketing authorisation, as an option for treating multiple myeloma, that is, for ‘adult patients with relapsed and/or refractory multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent